UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000000685
Receipt number R000000821
Scientific Title Stanford type B aortic dissection patients with normally hypotensive medical therapy and pitavastatin treatment effect.
Date of disclosure of the study information 2007/06/01
Last modified on 2018/12/05 17:22:39

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Stanford type B aortic dissection patients with normally hypotensive medical therapy and pitavastatin treatment effect.

Acronym

Stanford type B aortic dissection patients with pitavastatin treatment trial (STANP trial)

Scientific Title

Stanford type B aortic dissection patients with normally hypotensive medical therapy and pitavastatin treatment effect.

Scientific Title:Acronym

Stanford type B aortic dissection patients with pitavastatin treatment trial (STANP trial)

Region

Japan


Condition

Condition

Stanford type B acute aortic dissection patients transported within 48 hours of symptom onset , adaptable normally hypotensive medical therapy.

Classification by specialty

Cardiovascular surgery

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To evaluate the efficacy and safety of HMG-CoA reductase inhibitor therapy for aortic dissection patients in multiple institutions.

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Percent change and absolute change in the total diameter of the descending aorta (minor axis) by CT angiography

Key secondary outcomes

Percent change and absolute change in the following items
(1)Threatened rupture
(2)Surgical operation
(3)Serum lipid profile (LDL-C, triglyceride, HDL-C)
(4)Serum creatinine
(5)Correlation with the total diameter of descending aorta (minor axis) and serum lipid profile or serum creatinine
(6)All-cause mortalities
(7)Evaluation of adverse events
(8)Laboratory test abnormalities


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Open -no one is blinded

Control

Active

Stratification

YES

Dynamic allocation

YES

Institution consideration

Institution is not considered as adjustment factor.

Blocking


Concealment

Central registration


Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Standard hypotensive medical therapy with pitavastatin 2 mg daily for a period of 12 months

Interventions/Control_2

Standard hypotensive medical therapy for a period of 12 months

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

(1) Stanford type B acute aortic dissection patients transported within 48 hours after onset.
(2) Standard hypotensive medical therapy
(3) Greater than 20 years old at time of consent.
(4) Provide voluntary written informed consent for participation in the study after being fully informed.

Key exclusion criteria

(1) Patients with the total diameter of descending aorta (minor axis) by CT angiography more than 50mm.
(2) Marfan's syndrome patients
(3) Patients with continuous pain.
(4) Patients with unstable vital signs.
(5) Patients with signs or symptoms of organ ischemia
(6) Fasting serum levels of TC >/= 250 mg/dL.
(7) Known hypersensitivity or history of clinically significant adverse reactions to any component of study drugs.
(8) Patients with hepatopathy (ALT >/=100 IU/L) or biliary obstruction with the following conditions - acute hepatitis, acute exacerbation of chronic hepatitis, hepatic cirrhosis, hepatoma, jaundice.
(9) Pregnant, possibly pregnant, or lactating.
(10) Patients with significant renal dysfunction (serum creatinine >/= 2.0 mg/dL) or renal dialysis.
(11) Patient who is judged by the investigator to be inappropriate for inclusion in the study.

Target sample size

100


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Koichi Tabayashi

Organization

Tohoku University, Graduate School of Medicine

Division name

Cardiovascular Surgery

Zip code


Address

2-1, SEIRYO-CHO, AOBAKU, SENDAI, MIYAGI 980-8575

TEL

022-717-7222

Email

konosuke.s@med.tohoku.ac.jp


Public contact

Name of contact person

1st name
Middle name
Last name Naotaka Motoyoshi

Organization

STANP trial staff

Division name

Cardiovascular Surgery, Tohoku University, Graduate School of Medicine

Zip code


Address

2-1, SEIRYO-CHO, AOBAKU, SENDAI, MIYAGI 980-8575

TEL

022-717-7222

Homepage URL


Email

motoyoshi_n810@yahoo.co.jp


Sponsor or person

Institute

Cardiovascular Surgery, Tohoku University, Graduate School of Medicine

Institute

Department

Personal name



Funding Source

Organization

None

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2007 Year 06 Month 01 Day


Related information

URL releasing protocol


Publication of results

Published


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2007 Year 04 Month 02 Day

Date of IRB


Anticipated trial start date

2007 Year 06 Month 01 Day

Last follow-up date


Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2007 Year 04 Month 18 Day

Last modified on

2018 Year 12 Month 05 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000000821


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name